Taiwan Ming-Kuei Jang, founder and CEO of Aprinoia, a very promising Taiwan-based company focused on the development of groundbreaking imaging tracers and therapeutics targeting tau-related neurodegenerative diseases, provides insights into the company’s rapid development over the past two years, its R&D strategy, and its eagerness to partner with both academia and…
Japan Eric Delarge, general manager and representative director of Servier Japan, recently became the first member of the international pharma industry to join bioIPSeeds, an innovative tool aiming to foster early stage collaboration between academia and the global industry, which also stands as the first application of the blockchain technology in…
Taiwan Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), provides insights into the recent development of the country’s innovative biopharmaceutical industry, while she also highlights TRPMA’s eye-catching initiative to promote international collaboration between Taiwan’s academia and the global industry, thanks to the recent set up of the association’s…
Taiwan Carol Cheng, COO of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), the association gathering 28 Taiwan-based, R&D-driven biopharmaceutical companies, highlights the association’s eye-catching initiative to boost international collaboration between academia and the global industry, thanks to the recent set up of the BioIPSeeds® platform, which proudly stands as the first…
Taiwan James Chen, founder and Chairman of the board of Vetco, the first Taiwan-based veterinary company to have successfully developed an innovative veterinary oncology product, documents the main specificities of Vetco’s flagship product, Antican®, as well as his strategy to bring this ground-breaking treatment onto the most advanced animal health markets…
Taiwan Johnsee Lee, founder, CEO, and president of Personal Genomics and its sister company Quark Biosciences, provides insights into the company’s proprietary Optoelectronic Sequencing (OES) technology, which can perform whole genome sequencing thousand times faster than existing technologies and increase read length twentyfold in comparison to sequencing products currently on the…
Taiwan Ben Chien, Chairman, President and CEO, of Foresee Pharmaceuticals, one of Taiwan’s most vibrant success stories, discusses how Foresee has achieved successful phase III results for its prostate cancer treatment, FP-001, IPOed and entered into a partnership agreement with Ferring in the last year alone. In addition, he discloses how…
Taiwan Dr. Tzu-Ling (Karen) Tseng, CEO of Bio Preventive Medicine Corporation in Taiwan, discusses the innovative technology of its patented biomarkers, the success of DNlite and company’s strategy to grow through partnerships with global pharmaceutical companies. What was your vision when you founded Bio Preventive Medicine Corporation (BPM) in 2014? Can…
Taiwan C.Y. Cheng, chairman and president of Formosa Laboratories, shares exciting news about the establishment of a new drug development company, Formosa Pharmaceuticals. He explains how the know-how gained from running a successful international API production business will help Formosa avoid the typical mistakes that young R&D companies face. Mr. Cheng,…
Taiwan Chih-Yi Weng, chairlady and CEO of Charsire Biotechnology, one of Taiwan’s leading biotech companies focused on the development of botanical new drugs as well as topical and personal care products, provides insights into the company’s unique business model and its promising and maturing R&D pipeline, while Charsire was ranked in…
Switzerland The southern Swiss canton of Ticino does not have the life science reputation of Basel, Zurich or Geneva, but benefits from an open business environment, strategic location, and a thriving network of pharmaceutical SMEs. “Ticino is really a perfect example of the excellence of Swiss SMEs in the pharma industry, as…
Taiwan In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug development process. She also elaborates on the key next steps that lie ahead for OBI Pharma’s flagship immuno-oncology therapy, Adagloxad…
See our Cookie Privacy Policy Here
